Viridian Therapeutics, Inc.\DE (VRDN) insider trading
Every open-market stock purchase and sale by Viridian Therapeutics, Inc.\DE executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders bought $30M over the last 12 months (2 buys).
- Insiders sold $70.8K over the last 12 months (1 sale).
- Last insider buy: Fairmount Funds Management LLC (10% owner), $20M, 5 months ago.
Last 12 months: insiders bought $30M (2 buys) and sold $70.8K (1 sale). Last close $15.73 on Jun 7, 2026.
Recent VRDN insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| May 11, 2026 | Fairmount Funds Management LLC (10% owner) | Bought | $20M |
| Mar 3, 2026 | Stephen F. Mahoney (CEO) | Sold (not open market) | $224K |
| Mar 3, 2026 | Stephen F. Mahoney (CEO) | Sold (not open market) | $224K |
| Mar 3, 2026 | Thomas W. Beetham (COO) | Sold (not open market) | $92K |
| Mar 3, 2026 | Thomas W. Beetham (COO) | Sold (not open market) | $92K |
| Mar 3, 2026 | Seth Harmon (CFO) | Sold (not open market) | $61.3K |
| Mar 3, 2026 | Seth Harmon (CFO) | Sold (not open market) | $61.3K |
| Mar 3, 2026 | Jennifer Tousignant (C-suite exec) | Sold (not open market) | $50.6K |
| Mar 3, 2026 | Jennifer Tousignant (C-suite exec) | Sold (not open market) | $50.5K |
| Mar 3, 2026 | Stephen F. Mahoney (CEO) | Bought (not open market) | — |
| Mar 3, 2026 | Jennifer Tousignant (C-suite exec) | Bought (not open market) | — |
| Mar 3, 2026 | Thomas W. Beetham (COO) | Bought (not open market) | — |
| Mar 3, 2026 | Seth Harmon (CFO) | Bought (not open market) | — |
| Mar 2, 2026 | Seth Harmon (CFO) | Bought (not open market) | — |
| Mar 2, 2026 | Seth Harmon (CFO) | Bought (not open market) | — |
| Mar 2, 2026 | Radhika Tripuraneni (C-suite exec) | Bought (not open market) | — |
| Mar 2, 2026 | Radhika Tripuraneni (C-suite exec) | Bought (not open market) | — |
| Mar 2, 2026 | Stephen F. Mahoney (CEO) | Bought (not open market) | — |
| Mar 2, 2026 | Stephen F. Mahoney (CEO) | Bought (not open market) | — |
| Mar 2, 2026 | Thomas W. Beetham (COO) | Bought (not open market) | — |
| Mar 2, 2026 | Thomas W. Beetham (COO) | Bought (not open market) | — |
| Mar 2, 2026 | Jennifer Tousignant (C-suite exec) | Bought (not open market) | — |
| Mar 2, 2026 | Jennifer Tousignant (C-suite exec) | Bought (not open market) | — |
| Dec 31, 2025 | Jennifer Tousignant (C-suite exec) | Sold | $70.8K |
| Oct 23, 2025 | Fairmount Funds Management LLC (10% owner) | Bought | $10M |
Who's trading VRDN
- Fairmount Funds Management LLC, 10% owner: bought $30M (2 buys), last May 11, 2026
- Seth Harmon, CFO: other filings, last Mar 3, 2026
- Jennifer Tousignant, C-suite exec: sold $70.8K (1 sale), last Mar 3, 2026
- Stephen F. Mahoney, CEO: other filings, last Mar 3, 2026
- Thomas W. Beetham, COO: other filings, last Mar 3, 2026
- Radhika Tripuraneni, C-suite exec: other filings, last Mar 2, 2026
Get free alerts when an insider at Viridian Therapeutics, Inc.\DE files a new trade →